NCAM1 and acute myeloid leukemia: In acute myeloid leukemia (AML) patients administered with low-dose IL-2 at 16,400 U/kg subcutaneously three times for 18 months, CD3-CD16-CD56bright and CD3-CD16+CD56+ NK cells increased in the blood, and the expression of NKp30 and NKp46 also increased.